Gian Life Care Ltd

🗓️ Meeting Details

• Board meeting scheduled for 14 February 2026 in Kanpur.

📊 Financial Performance

• Approval of unaudited standalone and consolidated financial results for quarter ended 31 December 2025.

Financial Performance 📊

• Standalone revenue was Rs 66.00 lakhs in Q2 FY26, down 66% YoY from Rs 194.67 lakhs.
• Standalone net loss was Rs 46.20 lakhs in Q2 FY26 versus profit of Rs 14.19 lakhs in Q2 FY25.
• Consolidated revenue from operations was Rs 66.01 lakhs in Q2 FY26, down from Rs 194.67 lakhs in Q2 FY25.
• Consolidated net loss was Rs 51.21 lakhs in Q2 FY26 versus profit of Rs 11.73 lakhs in Q2 FY25.
• Standalone EBITDA loss before tax was Rs 9.72 lakhs in Q2 FY26 versus profit of Rs 16.76 lakhs in Q2 FY25.
• Standalone total expenses rose to Rs 125.04 lakhs in Q2 FY26 from Rs 94.83 lakhs in Q1 FY26.

Balance Sheet & Cash Flow 💰

• Standalone cash and cash equivalents were Rs 744.46 lakhs as of Sept 30, 2025.
• Consolidated cash and cash equivalents were Rs 745.77 lakhs as of Sept 30, 2025.
• Standalone long-term borrowings increased to Rs 229.74 lakhs as of Sept 30, 2025, from Rs 169.75 lakhs a year ago.
• Consolidated long-term borrowings increased to Rs 281.86 lakhs as of Sept 30, 2025, from Rs 217.19 lakhs a year ago.
• Trade payables rose to Rs 424.49 lakhs standalone and Rs 442.39 lakhs consolidated as of Sept 30, 2025.
• Operating cash flow was positive Rs 60.72 lakhs standalone and Rs 58.33 lakhs consolidated for H1 FY26.

Auditor & Risks ⚠️

• Auditor highlighted Rs 743.78 lakhs cash balance with unpaid statutory dues of Rs 426.66 lakhs and NPA bank loan of Rs 359.78 lakhs.
• Auditor unable to verify cash balance existence due to lack of physical verification and explanations.

Other Financial Metrics

• Standalone basic EPS was negative Rs 0.45 in Q2 FY26 versus positive Rs 0.14 in Q2 FY25.
• Consolidated basic EPS was negative Rs 0.50 in Q2 FY26 versus negative Rs 0.45 in Q2 FY25.
• Finance costs increased to Rs 9.28 lakhs standalone and Rs 12.04 lakhs consolidated in Q2 FY26.

Business Model

• Company operates in healthcare diagnostics through subsidiaries Gian Satguru Pathology LLP and Gian Path Lab (India) Pvt. Ltd.

Financial Performance

• Board approved unaudited standalone and consolidated results for quarter/half year ended September 30, 2025.
• Standalone loss: Rs. 46.20 lakhs (quarter), Rs. 40.75 lakhs (half year); consolidated loss: Rs. 51.21 lakhs (quarter), Rs. 45.82 lakhs (half year).
• Earnings per share (basic) for quarter: Rs. (0.45) standalone, Rs. (0.50) consolidated.
• Total revenue for quarter: Rs. 75.32 lakhs standalone, Rs. 75.33 lakhs consolidated.

Auditor Remarks ️

• Auditor issued limited review with qualification on cash balance approx. Rs. 743.78 lakhs.
• Statutory dues of Rs. 426.66 lakhs and NPA bank loan of Rs. 359.78 lakhs remain unpaid.
• Auditor unable to verify cash balance due to lack of physical verification and audit evidence.

Balance Sheet Highlights

• Standalone total assets: Rs. 3,377.42 lakhs; consolidated total assets: Rs. 3,415.41 lakhs.
• Standalone long-term borrowings: Rs. 229.74 lakhs; consolidated long-term borrowings: Rs. 281.86 lakhs.
• Cash and cash equivalents: Rs. 744.46 lakhs standalone; Rs. 745.77 lakhs consolidated.

Cash Flow Highlights

• Net cash from operating activities: Rs. 60.72 lakhs standalone; Rs. 58.33 lakhs consolidated.
• Net cash from investing activities: Rs. 24.83 lakhs standalone; Rs. 24.81 lakhs consolidated.
• Net cash used in financing activities: Rs. 35.45 lakhs standalone; Rs. 28.47 lakhs consolidated.
• Cash and cash equivalents at period end: Rs. 766.49 lakhs standalone; Rs. 767.81 lakhs consolidated.

Governance and Corporate Actions

• No changes in directors, auditors, or key management personnel.
• No dividend declarations, capital raising, buybacks, or major investments/disposals.
• Board meeting held on January 28, 2026, approved the above results.

🗓️ Meeting Details

• Board meeting scheduled for 21 February 2026 in Kanpur.

📊 Financial Results

• Approval of unaudited standalone and consolidated financial results for Q2 and Q3 ending 30 September 2025 and 31 December 2025.